Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
50 hedge funds and large institutions have $279M invested in Harpoon Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 6
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more capital invested
Capital invested by funds: $196M → $279M (+$82.9M)
19% more funds holding
Funds holding: 42 → 50 (+8)
18.11% more ownership
Funds ownership: 58.32% → 76.43% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$12.9M |
| 2 |
BlackRock
New York
|
+$2.05M |
| 3 |
Renaissance Technologies
New York
|
+$1.28M |
| 4 |
Millennium Management
New York
|
+$1.23M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$710K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.42M |
| 2 |
DM
Deerfield Management
New York
|
-$3.61M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$2.02M |
| 4 |
Goldman Sachs
New York
|
-$158K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$79.6K |
HARP Hedge Fund Activity: Q4 2019 in Review
50 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q4 2019, worth a combined $279M — up 42% from $196M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new HARP positions and 5 closed out — a net gain of 8 holders — while 21 added to existing stakes and 6 trimmed.
The largest buyer was Artal Group, opening a new position worth an estimated $12.9M. The largest seller was EcoR1 Capital, cutting an estimated $8.42M.
- 50 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q4 2019, up from 42 in Q3 2019.
- Funds reported $279M of Harpoon Therapeutics, Inc. Common Stock stock for Q4 2019, up 42% quarter-over-quarter.
- 13 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q4 2019 and 5 closed out, a net change of +8 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q4 2019 was Artal Group, an estimated $12.9M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q4 2019 was EcoR1 Capital, an estimated $8.42M sold.
Based on aggregated 13F filings for Q4 2019.